遥遥领先！创新药“新势力”——港股通创新药ETF（520880）续涨逾4%，再登全市场ETF涨幅第一！

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) reaching a historical high, increasing by 4.18% [1] - The Hong Kong Stock Connect Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has seen a year-to-date increase of 107.56%, outperforming other innovative drug indices [2][3] - Major stocks in the innovative drug sector, such as Innovent Biologics, CSPC Pharmaceutical Group, and WuXi AppTec, have shown significant gains, with Innovent Biologics rising over 3% and others increasing by more than 1% [1][2] Group 2 - Analysts indicate that the innovative drug sector remains a clear trend within the pharmaceutical industry, with substantial growth potential and attractive valuations, suggesting increased foreign investment in Hong Kong innovative drugs [4] - The performance of the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has varied over the years, with historical declines in 2021, 2022, 2023, and 2024, but the current year shows a strong recovery [3]